GENITOURINARY CANCERS

Notably, patients in EV-302 who converted from PR to CR achieved survival outcomes similar to those who achieved CR directly.

The phase 3 POTOMAC study was the supporting trial for the FDA approval of the durvalumab combination for BCG-naive NMIBC.

Oncologists weigh second-line options after ICI failure in metastatic ccRCC, spotlighting lenvatinib/everolimus, new agents, and ICI rechallenge.

"This [TALAPRO-2] analysis represents the first...patient-level analysis to evaluate rPFS–OS correlation for a PARP inhibitor in first-line mCRPC," said Neeraj Agarwal, MD.

Durvalumab plus BCG induction/maintenance showed a tolerable safety profile in BCG-naive NMIBC, according to the phase 3b PATAPSCO study.

The study is the first randomized, prospective head-to-head comparison of the cognitive effects of two androgen receptor pathway inhibitors.

The sBLA for nogapendekin alfa inbakicept is supported by 36-month follow-up data from cohort B of the QUILT-3.032 trial.

Investigators urge caution in interpreting these results, acknowledging the inherent limitations of unanchored, population-adjusted indirect trial comparisons.

The TRITON3 update supports rucaparib's role as an established option in the post-ARPI, pre-chemotherapy BRCA+ mCRPC setting.

“These findings support the potential for a treatment holiday with enzalutamide combination [therapy] in high-risk biochemically recurrent prostate cancer," said Neal D. Shore, MD.

SunRISe-4: Genomic disease burden, TMB, and PD-L1 expression linked to pathologic overall response to neoadjuvant gemcitabine intravesical system plus cetrelimab in MIBC.

The pembrolizumab/BCG combo yielded clinical complete responses at 6 months in over 90% of very high-risk BCG-naive NMIBC patients.

In ARASEC, darolutamide plus ADT significantly improved survival and disease control versus ADT alone in mHSPC, complementing ARANOTE outcomes.

The FDA approved atezolizumab for the adjuvant treatment of muscle invasive bladder cancer with ctDNA molecular residual disease after cystectomy.

UGN-103 (mitomycin) for intravesical solution sustained disease control through 6 months in the UTOPIA trial in recurrent intermediate-risk LG-NMIBC.

The phase 3 VOLGA trial showed perioperative durvalumab plus neoadjuvant enfortumab vedotin reduced the risk of death in muscle-invasive bladder cancer.

Mitomycin for intravesical solution demonstrated durable responses in 36-month follow-up data from the phase 3 ENVISION trial.

Sexual activity, sexual desire, and physical function were improved by testosterone replacement therapy in men with hypogonadism post-prostatectomy.

Dr Stein reviews PEACE-3 data supporting radium-223 plus enzalutamide in mCRPC and the role of bone-protecting agents in this setting.

Interim data from the LEGEND pivotal cohort show detalimogene achieved complete responses in more than half of patients with BCG-unresponsive non-muscle invasive bladder cancer.

S-HIFU achieved 71% ADT-free survival at 30 months in recurrent prostate cancer post-radiation, with better outcomes in patients with lower PSA and Gleason scores.

The FDA's Oncologic Drugs Advisory Committee voted in favor 7 to 1 that benefits of capivasertib outweighed risks.

Mark Stein, MD, explores managing mHSPC through PSMA PET imaging, tumor burden assessment, and AMPLITUDE trial data while considering clinical context.

Phase 1 trial of JANX014, a PSMA-targeted T-cell engager, begins in mCRPC, building on prior safety data to expand treatment strategies.

The FDA has granted a priority review to the supplemental biologics license application for enfortumab vedotin/pembrolizumab to all patients with MIBC regardless of cisplatin eligibility.